A presurgical phase II study on activity of metformin on breast cancer cell proliferation

Submission date	Recruitment status No longer recruiting	Prospectively registered		
21/07/2011		Protocol		
Registration date 05/08/2011	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
23/10/2020	Cancer			

Plain English summary of protocol

Background and study aims

Metformin is a commonly used, cheap and safe drug for treating diabetes. Research has shown that metformin use seems to be associated to a reduction in breast cancer risk. We are interested in investigating the effect of metformin given for 4 weeks in non-diabetic patients with breast cancer.

Who can participate?

Breast cancer patients aged over 18

What does the study involve?

Participants are randomly allocated to be treated with either metformin or a placebo (dummy) drug until they undergo surgery. The effect of the drug on the cancer cells and on various blood parameters is measured.

What are the possible benefits and risks of participating?

The expected risks are mainly gastrointestinal symptoms (diarrhea and nausea), so patients are asked to take a half dose during the first 3 days of treatment and then to continue to full dose if no symptoms occur. There is a very rare risk of lactic acidosis, an acute metabolic dysfunction which may happen especially in subjects with kidney disease.

Where is the study run from?

European Institute of Oncology, Milan (Italy)

When is the study starting and how long is it expected to run for? December 2008 to September 2011

Who is funding the study?

The Italian League against Cancer and the Ministry of Health. Drug and placebo are provided at no cost by Laboratori Guidotti SpA, Pisa (Italy).

Who is the main contact? Dr Bernardo Bonanni bernardo.bonanni@ieo.it

Contact information

Type(s)

Scientific

Contact name

Dr Bernardo Bonanni

Contact details

Divisione di Prevenzione e Genetica Oncologica Istituto Europeo di Oncologia via Ripamonti, 435 Milan Italy 20141

Ξ

bernardo.bonanni@ieo.it

Additional identifiers

EudraCT/CTIS number

2008-004912-10

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

IEO S425/408

Study information

Scientific Title

A presurgical phase II study on activity of metformin on breast cancer cell proliferation

Study objectives

We assess the antiproliferative activity of metformin in a window-of-opportunity trial in non-diabetic women with breast cancer candidates to surgery.

Ethics approval required

Old ethics approval format

Ethics approval(s)

European Institute of Oncology IRB, 16/10/2008

Study design

Randomized double-blind placebo-controlled phase II presurgical study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Breast cancer

Interventions

- 1. Patients are randomized in a double blind fashion to metformin (850 mg bid) or placebo and treated for 4 weeks
- 2. During the first three days of treatment patients are asked to take half dose (850 mg/die) in order to adapt to gastrointestinal symptoms

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Metformin

Primary outcome measure

- 1. The short-term response in the proliferative antigen Ki-67 LI, which is increasingly being used to screen active drugs in breast cancer because of its prognostic value and its postulated role in predicting the efficacy of anti cancer drugs
- 2. Percent change in Ki-67 LI between pretreatment biopsy and post-treatment surgical specimen

Secondary outcome measures

- 1. Effect of metformin on Ki-67 based on change in Homa index
- 2. Effect of metformin on circulating biomarkers (lipid profile, CRP, testosterone, adypokines, C-peptide, insulin, glycemia)
- 3. Evaluation of the antiproliferative activity of metformin on hyperplastic, dysplastic and malignant breast tissue

Overall study start date

01/12/2008

Completion date

30/09/2011

Eligibility

Key inclusion criteria

- 1. Age >18 years
- 2. Performance status=0 (Southwest Oncology Group [SWOG])
- 3. Histologically-confirmed breast cancer not candidate to neoadjuvant therapy, no prior treatment for breast cancer
- 4. Signed informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Female

Target number of participants

200

Total final enrolment

274

Key exclusion criteria

- 1. Previous treatment for breast cancer, including chemotherapy and endocrine therapy
- 2. Known severe hypersensitivity to metformin or any of the excipients of this product
- 3. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or in situ cervical cancer
- 4. As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) that would prevent subjects from undergoing any of the treatment options or would prevent prolonged follow-up
- 5. Diabetes mellitus and diabetes treatments
- 6. Creatinine >1.2 mg/dl and/or Glomerular filtration > 60 ml/min/1.73m2
- 7. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
- 8. Pregnancy or breast feeding (women of child-bearing potential must have a negative pregnancy test within 7 days before the start of study treatment and should practice acceptable methods of birth control to prevent pregnancy during and after study treatment)
- 9. Treatment with a non-approved or investigational drug within 30 days before day 1 of study treatment

Date of first enrolment

01/12/2008

Date of final enrolment

30/09/2011

Locations

Countries of recruitment

Italy

Study participating centre Istituto Europeo di Oncologia

Milan Italy 20141

Sponsor information

Organisation

European Institute of Oncology (Istituto Europeo di Oncologia) (Italy)

Sponsor details

Via Ripamonti, 435 Milan Italy 20141 +39 02 574 891 carlo.ciani@ieo.it

Sponsor type

Research organisation

Website

http://www.ieo.it/Italiano/Pages/Default.aspx

ROR

https://ror.org/02vr0ne26

Funder(s)

Funder type

Charity

Funder Name

Italian League Against Cancer (ref: 14/08)

Funder Name

Ministero della Salute

Alternative Name(s)

Italian Ministry of Health, Italy Ministry of Health, Ministry of Health of Italy, Ministry of Health - Italy, Ministry of Health, Italy

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Italy

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2014	23/10/2020	Yes	No